MGMT and neoplasm: Targeted silencing of MGMT in pre-radiated tumor sites using our novel approach, without measurable MGMT silencing in non-radiated sites, may limit systemic toxicities associated with prior approaches to deplete MGMT in combination with temozolomide [18–20].